Results 11 to 20 of about 3,972 (148)

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

BMC Cancer, 2022
Background Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers in a wide array of tumors.
James C. H. Yang, Marcia S. Brose, Gilberto Castro, Edward S. Kim, Ulrik N. Lassen, Serge Leyvraz, Alberto Pappo, Fernando López-Ríos, John A. Reeves, Marc Fellous, Frédérique Penault-Llorca, Erin R. Rudzinski, Ghazaleh Tabatabai, Gilles Vassal, Alexander Drilon, Jonathan Trent   +15 more
doaj   +3 more sources

Three locally invasive infantile fibrosarcoma cases treated with larotrectinib [PDF]

The Turkish Journal of Pediatrics
Background. Infantile fibrosarcoma is a rapidly growing soft tissue tumor, often managed by surgical resection, with chemotherapy and radiotherapy as additional options.
Hikmet Gülşah Tanyıldız, Yasin Yılmaz, Doğa Dalay, Şifa Şahin, Serap Karaman, Ayşegül Ünüvar, Zeynep Karakaş, Deniz Tuğcu   +7 more
doaj   +2 more sources

Development and validation of an LC-MS/MS method for monitoring larotrectinib, a tropomyosin-related kinase inhibitor, in mouse and human plasma and application to pharmacokinetic studies

Journal of Analytical Science and Technology, 2020
Larotrectinib is an orally administered drug and the first and only selective pan-tropomyosin receptor kinase (TRK) inhibitor in clinical development to treat cancer patients harboring a neurotrophic receptor tyrosine kinase gene fusion.
Yoon-Jee Chae, Yoo-Kyung Song, Song-Hee Chae, Min Ju Kim, Jong Soon Kang, Jae-Young Lee, Tae-Sung Koo, Kyeong-Ryoon Lee   +7 more
doaj   +2 more sources

Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer [PDF]

, 2022
Larotrectinib and entrectinib are tumor-agnostic tropomyosin receptor kinase (TRK) inhibitors that are indicated for the treatment of advanced or metastatic solid tumor cancers with neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
Brose, Marcia S., Carlson, Josh J, Sullivan, Sean D, Italiano, Antoine, Lassen, Ulrik, Carlson, Josh J., Brose, Marcia S, Sullivan, Sean D., Federman, Noah, Kummar, Shivaani   +9 more
core   +3 more sources

Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data. [PDF]

Endocr Relat Cancer
Larotrectinib is a first-in-class, highly selective, central nervous system-active tropomyosin receptor kinase (TRK) inhibitor approved for tumour-agnostic use in TRK fusion cancer.
Waguespack SG, Brose MS, Lin JJ, McDermott R, Almubarak M, Bauman J, Casanova M, Kummar S, Lee SH, Rieke DT, Oh DY, Qi C, Neu N, Burcoveanu DI, Mussi CE, Drilon A, Hong DS, Cabanillas ME.   +17 more
europepmc   +6 more sources

The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database

Biomedicines, 2023
The first-generation tropomyosin receptor kinase (TRK) inhibitors, larotrectinib and entrectinib, represent exciting new developments in cancer treatment that offer relevant, rapid, and long-lasting clinical benefits.
Valerio Liguori, Mario Gaio, Alessia Zinzi, Cecilia Cagnotta, Consiglia Riccardi, Giovanni Docimo, Annalisa Capuano   +6 more
doaj   +1 more source

TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs

Pharmaceuticals, 2021
Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the ...
Sun-Young Han
doaj   +1 more source

Resolution on the results of Advisory Board “Searching the effective methods of testing and treating patients with NSCLC caused by NTRK gene fusions“

Медицинский совет, 2022
The Advisory Board was held on December 24, 2021. The molecular genetic research lead specialists and national lead oncologists discussed issues of diagnosis of NTRK gene translocations in patients with non-small cell lung cancer (NSCLC), as well as ...
E. V. Artamonova, V. V. Breder, L. Yu. Vladimirova, I. A. Demidova, E. N. Imyanitov, К. К. Laktionov, M. P. Matrosova, S. V. Orlov, E. О. Rodionov, D. D. Sakaeva, M. I. Sekacheva, A. V. Smolin, N. V. Fadeeva, M. L. Filipenko   +13 more
doaj   +1 more source

High-Grade Endometrial Stromal Sarcoma with <i>NTRK</i> Fusion and Response to Larotrectinib: A Case Report. [PDF]

J Clin Med
Background: High-grade endometrial stromal sarcoma (HGESS) is a rare and aggressive uterine mesenchymal tumor with a significant potential for recurrence and metastasis. Advances in molecular pathology have identified recurrent gene fusions involving the
Bar-Noy T, Lozano-Franco R, Nagaria TS, Brodeur MN, Salvador S, Lau S.   +5 more
europepmc   +2 more sources

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

Current Oncology, 2021
The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine E. Simmons, Denis Soulieres, Emina Emilia Torlakovic, Ming-Sound Tsao   +17 more
doaj   +1 more source